Study of velinotamig for immune blood disorders
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new drug called velinotamig for adults with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that came back or didn't get better after standard treatments. The goal is to see if it can help control the immune system and improve blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have ITP or wAIHA that is active and has not responded to or returned after standard treatments.
- You are able to do everyday activities (ECOG performance status 0, 1, or 2).
- Your blood counts and organ function meet certain minimum levels, like a hemoglobin of at least 6.5 g/dL.
- You do not have serious infections like active hepatitis B or C, HIV, or active tuberculosis.
- You have not had a previous treatment targeting BCMA or a solid organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an IV medicine called V-IMMUNE® for people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if V-IMMUNE® can safely raise platelet counts in both children and adults.
This trial tests a new drug called CM336 for people with immune thrombocytopenia (ITP) that hasn't responded well to other treatments. It aims to see if CM336 can safely help raise platelet counts and reduce bleeding risk.
This trial tests a new mRNA-based treatment for people with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The treatment aims to lower the immune attack and raise platelet counts.
This trial tests an investigational drug called NVG-2089 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if it safely raises platelet counts and improves bleeding symptoms.
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
This trial tests a combination of two drugs—avatrombopag and all-trans retinoic acid—in adults with persistent or chronic immune thrombocytopenia (ITP) whose platelet levels stay low despite prior treatments. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.